Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more favorable properties could aid in the creation of T-BsAbs with impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinklein, Nathan D., Pham, Duy, Schellenberger, Ute, Buelow, Ben, Boudreau, Andrew, Choudhry, Priya, Clarke, Starlynn C., Dang, Kevin, Harris, Katherine E., Iyer, Suhasini, Jorgensen, Brett, Pratap, Payal P., Rangaswamy, Udaya S., Ugamraj, Harshad S., Vafa, Omid, Wiita, Arun P., van Schooten, Wim, Buelow, Roland, Force Aldred, Shelley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601548/
https://www.ncbi.nlm.nih.gov/pubmed/30698484
http://dx.doi.org/10.1080/19420862.2019.1574521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601548/
https://www.ncbi.nlm.nih.gov/pubmed/30698484
http://dx.doi.org/10.1080/19420862.2019.1574521

Ejemplares similares